Chembio Diagnostics Stock Price, News & Analysis (NASDAQ:CEMI)

$6.75 -0.10 (-1.46 %)
(As of 11/17/2017 12:37 PM ET)
Previous Close$6.85
Today's Range$6.75 - $6.80
52-Week Range$5.05 - $7.05
Volume8,400 shs
Average Volume20,551 shs
Market Capitalization$84.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

About Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics logoChembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.


Industry, Sector and Symbol:
  • Industry: Diagnostic & Testing Substances Manufacturers
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:CEMI
  • CUSIP: N/A
  • Web: www.chembio.com
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 3.54%
  • Quick Ratio: 2.19%
Sales & Book Value:
  • Annual Sales: $17.87 million
  • Price / Sales: 4.65
  • Book Value: $1.21 per share
  • Price / Book: 5.58
Profitability:
  • Trailing EPS: ($0.57)
  • Net Income: ($13,340,000.00)
  • Net Margins: -32.42%
  • Return on Equity: -42.76%
  • Return on Assets: -34.54%
Misc:
  • Employees: 131
  • Outstanding Shares: 12,320,000
 
Frequently Asked Questions for Chembio Diagnostics (NASDAQ:CEMI)

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) issued its earnings results on Thursday, August, 11th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.75. The firm earned $3.27 million during the quarter, compared to the consensus estimate of $6.72 million. Chembio Diagnostics had a negative net margin of 32.42% and a negative return on equity of 42.76%. View Chembio Diagnostics' Earnings History.

Who are some of Chembio Diagnostics' key competitors?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:

  • John J. Sperzel III, President, Chief Executive Officer, Director (Age 52)
  • Richard J. Larkin, Chief Financial Officer (Age 58)
  • Sharon Klugewicz, President - Americas Region (Age 49)
  • Javan Esfandiari, Chief Science and Technology Officer (Age 48)
  • Tom Ippolito, Vice President - Regulatory Affairs, Quality Assurance and Quality Control (Age 52)
  • Paul Lambotte Ph.D., Vice President - Product Development (Age 64)
  • Michael K. Steele, Vice President - Business Development, Sales and Marketing (Age 48)
  • Katherine L. Davis, Non-Executive Independent Chairman of the Board (Age 58)
  • Gail S. Page, Director
  • Peter T. Kissinger Ph.D., Independent Director (Age 70)

Who owns Chembio Diagnostics stock?

Chembio Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (0.29%) and Benchmark Capital Advisors (0.27%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.

Who sold Chembio Diagnostics stock? Who is selling Chembio Diagnostics stock?

Chembio Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for Chembio Diagnostics.

Who bought Chembio Diagnostics stock? Who is buying Chembio Diagnostics stock?

Chembio Diagnostics' stock was purchased by a variety of institutional investors in the last quarter, including Benchmark Capital Advisors. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy Chembio Diagnostics stock?

Shares of Chembio Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of Chembio Diagnostics stock can currently be purchased for approximately $6.75.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $84.38 million and generates $17.87 million in revenue each year. The company earns ($13,340,000.00) in net income (profit) each year or ($0.57) on an earnings per share basis. Chembio Diagnostics employs 131 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at snorcott@chembio.com.


MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Chembio Diagnostics (NASDAQ:CEMI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A
Consensus Price Target History for Chembio Diagnostics (NASDAQ:CEMI)
Price Target History for Chembio Diagnostics (NASDAQ:CEMI)
Analysts' Ratings History for Chembio Diagnostics (NASDAQ:CEMI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/11/2016Benchmark Co.Set Price TargetBuy$9.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Chembio Diagnostics (NASDAQ:CEMI)
Earnings by Quarter for Chembio Diagnostics (NASDAQ:CEMI)
Earnings History by Quarter for Chembio Diagnostics (NASDAQ CEMI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.17)($0.18)$4.96 million$2.89 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.20)($0.13)$4.88 million$5.43 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.15)($0.21)$4.44 million$4.26 millionViewListenView Earnings Details
11/10/2016Q3 2016($0.17)($0.19)$3.76 million$3.75 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.86)$6.72 million$3.27 millionViewListenView Earnings Details
5/12/2016Q1($0.09)($0.03)$4.83 million$6.60 millionViewListenView Earnings Details
3/8/2016Q4($0.09)($0.07)$6.56 million$4.42 millionViewN/AView Earnings Details
11/12/2015Q3($0.09)($0.05)$6.77 million$6.89 millionViewListenView Earnings Details
8/6/2015Q2($0.03)($0.07)$7.53 million$6.72 millionViewN/AView Earnings Details
5/7/2015Q115($0.08)($0.07)$5.20 million$6.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.04)($0.05)$7.10 million$7.10 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.03)($0.03)$7.71 million$7.31 millionViewN/AView Earnings Details
8/7/2014Q2($0.02)($0.02)$6.25 million$7.42 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.02)($0.02)$6.87 million$5.81 millionViewN/AView Earnings Details
3/6/2014Q413$0.04($0.03)$7.05 million$7.86 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.04)($0.03)$5.56 million$5.39 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.06$0.04ViewN/AView Earnings Details
11/13/2012Q312$0.04($0.04)$6.11 million$5.01 millionViewN/AView Earnings Details
8/9/2012$0.05$0.04ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chembio Diagnostics (NASDAQ:CEMI)
2017 EPS Consensus Estimate: ($0.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.19)($0.19)($0.19)
Q2 20172($0.17)($0.15)($0.16)
Q3 20172($0.11)($0.09)($0.10)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Chembio Diagnostics (NASDAQ:CEMI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Chembio Diagnostics (NASDAQ CEMI)
Insider Ownership Percentage: 5.56%
Institutional Ownership Percentage: 30.57%
Insider Trades by Quarter for Chembio Diagnostics (NASDAQ:CEMI)
Insider Trades by Quarter for Chembio Diagnostics (NASDAQ:CEMI)
Insider Trades by Quarter for Chembio Diagnostics (NASDAQ CEMI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/28/2017Norman H PessinInsiderBuy36,250$5.48$198,650.00View SEC Filing  
6/15/2016Sharon W KlugewiczCOOSell3,000$8.40$25,200.00View SEC Filing  
6/1/2016Javan EsfandiariInsiderSell25,000$8.58$214,500.00View SEC Filing  
5/29/2015Javan EsfandiariInsiderSell20,000$4.50$90,000.00View SEC Filing  
11/19/2014Peter KissingerDirectorBuy1,800$4.31$7,758.00View SEC Filing  
2/26/2014Sharon W KlugewiczCOOBuy10,000$3.50$35,000.00View SEC Filing  
12/6/2013Javan EsfandiariSVPSell10,000$3.40$34,000.00View SEC Filing  
11/11/2013Lawrence A SiebertMajor ShareholderSell30,000$3.63$108,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Chembio Diagnostics (NASDAQ:CEMI)
Latest Headlines for Chembio Diagnostics (NASDAQ CEMI)
Source:
DateHeadline
Edited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 7:55 PM
ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 7:55 PM
CHEMBIO DIAGNOSTICS, INC. to Host Earnings CallCHEMBIO DIAGNOSTICS, INC. to Host Earnings Call
finance.yahoo.com - November 8 at 8:42 PM
Chembio Diagnostics Reports Third Quarter 2017 Financial ResultsChembio Diagnostics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 8:42 PM
Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017
finance.yahoo.com - November 7 at 8:03 PM
Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial ResultsChembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results
feeds.benzinga.com - November 1 at 9:28 AM
ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 3:41 PM
ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 5:50 PM
ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 11:39 AM
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 12:24 PM
Chembio Announces Return of President and CEO John SperzelChembio Announces Return of President and CEO John Sperzel
www.nasdaq.com - October 3 at 2:13 AM
Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM TestChembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test
finance.yahoo.com - October 2 at 4:09 PM
BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31
www.reuters.com - August 17 at 11:24 PM
Chembio Diagnostics (CEMI) CFO to RetireChembio Diagnostics (CEMI) CFO to Retire
www.streetinsider.com - August 17 at 6:23 PM
Chembio Diagnostics Announces Retirement of Chief Financial OfficerChembio Diagnostics Announces Retirement of Chief Financial Officer
finance.yahoo.com - August 17 at 6:23 PM
Chembio Diagnostics (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call TranscriptChembio Diagnostics' (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 5:29 PM
Chembio Diagnostics, Inc. (CEMI) Posts  Earnings Results, Misses Expectations By $0.02 EPSChembio Diagnostics, Inc. (CEMI) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 10 at 9:28 PM
Edited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:15 PM
Chembio Diagnostics Reports Second Quarter 2017 Financial ResultsChembio Diagnostics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:16 PM
Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017
finance.yahoo.com - August 8 at 4:49 PM
Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial ResultsChembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 6:35 PM
Gail S. Page Joins Chembio Diagnostics Board of DirectorsGail S. Page Joins Chembio Diagnostics Board of Directors
finance.yahoo.com - July 6 at 6:19 PM
Chembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory AgencyChembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory Agency
www.streetinsider.com - July 5 at 10:53 PM
Chembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory AgencyChembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory Agency
finance.yahoo.com - July 5 at 5:49 PM
Chembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market ProgramChembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market Program
www.streetinsider.com - June 27 at 9:31 PM
Chembio Diagnostics (CEMI) CEO John Sperzel on Q1 2017 Results - Earnings Call TranscriptChembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 4:24 PM
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual ReportCHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 7 at 4:16 PM
Q4 2016 Chembio Diagnostics Inc Earnings Release - After Market CloseQ4 2016 Chembio Diagnostics Inc Earnings Release - After Market Close
biz.yahoo.com - March 7 at 12:28 PM
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsCHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 28 at 4:27 PM
Form 8-K CHEMBIO DIAGNOSTICS, For: Jan 27Form 8-K CHEMBIO DIAGNOSTICS, For: Jan 27
www.streetinsider.com - January 29 at 2:25 AM
ADHD Doesnt MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed StudyADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study
www.rttnews.com - January 18 at 3:03 AM
2:06 pm Chembio Diagnostics amends the terms of its previously announced stock purchase agreement with RVR Diagnostics2:06 pm Chembio Diagnostics amends the terms of its previously announced stock purchase agreement with RVR Diagnostics
us.rd.yahoo.com - December 13 at 4:53 PM
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementCHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - November 9 at 10:36 PM
Chembio Diagnostics (CEMI) to Acquire RVR DiagnosticsChembio Diagnostics (CEMI) to Acquire RVR Diagnostics
www.streetinsider.com - November 6 at 8:57 AM
PTN Surges On Trial Data, PFE Dumps Cholesterol Drug, Watch Out For PRTAPTN Surges On Trial Data, PFE Dumps Cholesterol Drug, Watch Out For PRTA
www.rttnews.com - November 2 at 10:26 AM
ADHD Doesnt MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study GoalADHD Doesn''t MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study Goal
www.nasdaq.com - September 29 at 9:03 AM
Chembio Diagnostics (CEMI) Awarded CDC Contract for Zika, Dengue, and Chikungunya SurveillanceChembio Diagnostics (CEMI) Awarded CDC Contract for Zika, Dengue, and Chikungunya Surveillance
www.streetinsider.com - September 29 at 9:03 AM
Chembio Diagnostics (CEMI) Receives USDA Grant for Bovine TB POC Diagnostic Test DevelopmentChembio Diagnostics (CEMI) Receives USDA Grant for Bovine TB POC Diagnostic Test Development
www.streetinsider.com - September 26 at 4:24 PM

Social Media

Financials

Chart

Chembio Diagnostics (NASDAQ CEMI) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.